KIR2DL5A: A Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: KIR2DL5A

NCBI ID: G57292

KIR2DL5A

KIR2DL5A: A Potential Drug Target and Biomarker for Alzheimer's Disease

KIR2DL5A (KIR2DL5.3) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The KIR2DL5A protein is a key regulator of the immune response and has been shown to play a crucial role in the regulation of neuroimmune homeostasis.

Recent studies have identified KIR2DL5A as a potential drug target for the treatment of Alzheimer's disease. By targeting the KIR2DL5A protein, researchers are hoping to reduce the immune activation that occurs in the brains of people with Alzheimer's disease and slow the progression of the disease.

One of the ways that KIR2DL5A is thought to contribute to the development and progression of Alzheimer's disease is by promoting the recruitment of immune cells to the brain. This process, known as immune evasion, is thought to contribute to the development of neurodegeneration and the formation of neurofibrillary tangles that are hallmark hallmarks of Alzheimer's disease.

KIR2DL5A is also thought to play a role in the regulation of neuroimmune homeostasis, which is the balance between the effects of the immune system and the brain's immune cells. This is important because an imbalance in this system has been implicated in the development of various neurological disorders, including Alzheimer's disease.

Research has also shown that KIR2DL5A is expressed in the brains of people with Alzheimer's disease and that it is significantly over-expressed in comparison to healthy brain tissue. This suggests that KIR2DL5A may be a useful biomarker for the diagnosis and progression of Alzheimer's disease.

In addition to its potential as a drug target, KIR2DL5A is also of interest as a potential biomarker for Alzheimer's disease. Studies have shown that KIR2DL5A is significantly reduced in the brains of people with Alzheimer's disease compared to healthy brain tissue. This suggests that KIR2DL5A may be a useful biomarker for the diagnosis of Alzheimer's disease.

Overall, KIR2DL5A is a protein that is of interest as a potential drug target for the treatment of Alzheimer's disease due to its role in the development and progression of the disease and as a potential biomarker for the diagnosis of the disease. Further research is needed to fully understand the role of KIR2DL5A in the immune response and in the regulation of neuroimmune homeostasis.

Protein Name: Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 5A

Functions: Receptor on natural killer (NK) cells for HLA-C alleles. Inhibits the activity of NK cells thus preventing cell lysis

The "KIR2DL5A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIR2DL5A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets